Harbinger Health Begins New Clinical Study in Individuals at High Risk for Cancer
CAMBRIDGE, Mass., Dec. 5, 2023 /PRNewswire/ -- Harbinger Health ("Harbinger," "the Company"), a biotechnology company pioneering new technologies to fundamentally change cancer screening and detection, announced today a research agreement with the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute to advance the Company's technology for early-stage multi-cancer detection.
- With this agreement, Harbinger and the Hale Family Center will jointly conduct a clinical study of participants at high risk for cancer due to a family history of pancreatic cancer.
- Harbinger will test its proprietary blood-based cancer screening platform using blood samples from participants over a period of 30 months to model their risk level for the disease.
- Further, a personal or family history of pancreatic cancer carries an increased risk for other types of cancer, most notably breast cancer and cancers of organs in the gastrointestinal tract.
- Ultimately, we hope to one day provide high-risk individuals and medical providers with advanced tools to assess risk and detect multiple cancers before they are visible or symptomatic."